Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic Leukemia (CMML) is a rare blood disorder that combines features of myelodysplastic syndromes and myeloproliferative neoplasms.

It leads to increased monocytes and abnormal bone marrow function.

Overview And Clinical Background

CMML involves overproduction of monocytes in the blood and bone marrow.

It’s more common in older adults and progresses gradually.

Nature:Chronic disorder blending dysplasia and proliferation.

Cell type:Involves monocytes and immature blood precursors.

Early intervention improves survival outcomes.

Symptoms overlap with other marrow disorders.

Often discovered through abnormal blood counts.

Common symptom:Fatigue, anemia, or frequent infections.

Bleeding or bruising from low platelets.

Red flag:Sudden increase in white blood cell count or spleen enlargement.

Diagnosis is confirmed through bone marrow examination and cytogenetic tests.

Classification helps tailor therapy.

Imaging:Ultrasound or CT for spleen size assessment.

Lab tests:CBC, bone marrow aspirate, and cytogenetics.

Flow cytometry helps distinguish CMML from leukemia variants.

Treatment focuses on symptom control and preventing progression to acute leukemia.

Tailored to patient’s age and health.

Supportive care:Blood transfusions and antibiotics for infections.

Drug therapy:Hypomethylating agents or chemotherapy for advanced stages.

Stem cell transplant offers potential cure in eligible patients.

Prognosis varies by subtype and genetic profile.

Ongoing follow-up improves outcomes.

CureU Healthcare’s hematology team provides targeted CMML management and advanced marrow diagnostics.

CMML requires personalized treatment and close monitoring.

Early detection and care improve long-term quality of life.